摘要
目的 评价89SrCl2 对乳腺癌转移性骨痛的临床疗效。方法 对 86例乳腺癌骨转移患者按体重静脉注射89Sr 1.48～ 2 .2 2MBq/kg。结果 治疗后骨痛减轻或消失 72例 ,总有效率为83 72 % ;治疗后骨显像有 5 9.30 % (5 1例 )骨转移灶代谢减低 ,治疗前后ROI比值比较 ,P <0 .0 5。治疗后有 2 7.90 % (2 4例 )出现Ⅰ～Ⅱ度血液学毒性反应 ,对心、肝、肾功能几乎没有影响。结论 89Sr对缓解乳腺癌骨转移瘤疼痛有较好疗效 ,并有一定的治疗作用 ,副作用小 ,可重复用药。
Objective To evaluate the palliative effect of 89 Sr metastron on bone pain of metastatic breast cancer. Methods The total 86 patients had been treated by intravenous 89 Sr metastron at a dose of 1.48～2.22 MBq/kg. Results The bone pain vanished or eased in 72 cases after therapy. The effective rate was 83.72%(72/86). The number and the size of metastatic cancer nests decreased or vanished in 51 cases (51/86,59.3%). The ratios of counts of ROIs in the metastatic lesions to counts of ROIs in normal counterparts after treatment decreased signifi cantly ( P <0.05, Wilcoxon). Side effects:Ⅰ～Ⅱ degree toxic reaction of blood appeared in 24 cases(27.90%, 24/86). The damage of heart, liver and kidney was not observed. Conclusions The 89 Sr metastron has obvious effect on treating patients with bone pain of metastatic breast cancer, and the side effect is mild, and it can be used repeatedly. The results of this study indicate that 89 Sr metastron is a useful radionuclide for treating bone pain of metastatic cancer.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2001年第4期205-206,共2页
Chinese Journal of Nuclear Medicine
关键词
乳房肿瘤
骨肿瘤
肿瘤转移
锶
放射性同位素
放射疗法
Mammary neoplasms
Bone neoplasms
Neoplasm metastasis
Strontium radioisotopes
Radiotherapy
